Perspective Therapeutics Announces First Patient Dosed in

First patient with MC1R-positive metastatic melanoma treated with 212Pb-VMT01Preliminary data readout from dose escalation study expected Q4 2023 ...

Related Keywords

United States ,University Of Iowa ,Iowa ,Richland ,Coralville ,Chicago ,Illinois ,American ,Markus Puhlmann ,Zacharys Morris ,Thijs Spoor ,Company Phase ,Exchange Commission ,Perspective Therapeutics Inc ,University Of Wisconsin Bentson Research Fellowship ,Washington University ,Yale University ,Society Of Nuclear Medicine ,Department Of Energy ,University Of Wisconsin ,Saint Louis University ,Perspective Therapeutics ,Chief Executive Officer ,Vice Chair ,Endowed Professor ,Human Oncology ,Program Director ,Wisconsin Bentson Research Fellowship ,Principal Investigator ,Mayo Clinic ,Nuclear Medicine ,Molecular Imaging ,Annual Meeting ,Chief Medical Officer ,Maximum Tolerated Dose ,Maximum Feasible Dose ,Fast Track ,Transition Report ,Quarterly Report ,